💸 The Tape

Massachusetts lawmakers have reached a compromise on long-awaited cannabis legislation that would double the adult possession limit from one ounce to two ounces and overhaul the state’s regulatory framework for the adult-use market.

After months of negotiations, a bicameral conference committee approved the compromise version of the bill on Monday. Sen. Adam Gómez (D) and Rep. Daniel M. Donahue (D), co-chairs of both the conference committee and the Joint Cannabis Policy Committee, described the agreement as charting “a more promising path forward for cannabis regulation in our Commonwealth.”

The bill, if passed by both chambers this week and signed by Gov. Maura Healey (D), would represent the most significant update to Massachusetts cannabis law since adult-use legalization in 2016. It reflects the industry’s maturation while addressing oversight, equity, and economic sustainability.

Key Provisions of the Compromise Bill

The most visible change is the increase in personal possession limits from one ounce to two ounces of marijuana. This adjustment mirrors reforms in states like Colorado, where possession limits were expanded after the market matured and black-market activity declined.

Regulatory restructuring is another major component. The Cannabis Control Commission (CCC) would shrink from five members to three. The governor would gain authority to appoint all commissioners, replacing the current system that includes input from the treasurer and attorney general. At least one commissioner must have a background in social justice, while the others would bring expertise in public health, public safety, consumer regulation, or cannabis production and distribution.

The bill also modernizes licensing rules. The cap on licenses a single entity can hold would rise from three to six. The ownership threshold used to count toward license caps would increase from 10% to 20%. These changes aim to provide more flexibility for growing businesses while preventing excessive consolidation.

To promote fairness and accountability, the legislation directs regulators to maintain a list of “delinquent” cannabis businesses that have failed to pay debts to other operators for more than 60 days. Other licensees would be prohibited from doing business with delinquent operators until debts are resolved.

Social equity provisions receive renewed attention. The bill creates temporary exclusive opportunities for social equity businesses, including in the medical marijuana space, and supports innovative models such as employee-owned businesses. It also removes the vertical integration mandate for medical operators, which had created barriers for smaller entrants.

Additional measures include updated delivery rules for consistency across municipalities, more reasonable advertising practices within regulated channels, and directives for further study on hemp-derived products and workplace safety standards. A new portal for reporting illegal conduct and enhanced public reporting on health impacts and tax policy aim to improve transparency and accountability.

Industry Context and Implications

Massachusetts has one of the more established adult-use markets in the Northeast, but operators have faced challenges including high taxes, regulatory complexity, and competition from the illicit market. The proposed reforms seek to balance consumer access, public safety, and business viability.

Doubling possession limits could reduce demand for the illicit market by allowing adults to stock reasonable personal supplies legally. Streamlined licensing and ownership rules may help small and social equity businesses compete more effectively against larger players. Removing vertical integration requirements for medical operators could encourage specialization and innovation.

The restructuring of the CCC aims to create a more agile and focused regulatory body. With fewer commissioners and clearer mandates, the agency could potentially operate more efficiently while maintaining strong oversight.

For the broader industry, these changes signal that Massachusetts is adapting its framework to a maturing market. Similar reforms in other states have often led to improved compliance, reduced black-market activity, and more sustainable business models.

Path Forward and Outlook

With the conference committee’s approval, the bill is expected to receive final votes in both the House and Senate this week. Gov. Healey, who has generally supported measured cannabis reform, is widely expected to sign the legislation if it reaches her desk.

If enacted, the changes would take effect on varying timelines, with some provisions requiring regulatory rulemaking by the CCC.

The compromise represents a pragmatic middle ground: expanding consumer access and business flexibility while strengthening oversight and equity measures. It acknowledges that Massachusetts’ cannabis industry has evolved since 2016 and that the regulatory structure must evolve with it.

For patients, consumers, and businesses, the bill offers clearer rules, expanded opportunities, and a regulatory environment better suited to a mature legal market. Whether these reforms deliver their intended benefits will depend on effective implementation by the restructured CCC and continued collaboration between lawmakers, regulators, and industry stakeholders.

As one of the early legalizers in the Northeast, Massachusetts has the chance to set a thoughtful example for how established cannabis markets can modernize while preserving public health and safety priorities.

Source: Marijuana Moment

📈 Dog Walkers

SAFER Is Back

The SAFER Banking Act is back in Congress, reintroduced this week with 14 initial Senate cosponsors—eight Democrats and six Republicans—marking the eighth attempt since 2013 to solve one of the cannabis industry’s most persistent problems: access to basic financial services.

Sponsors argue that President Trump’s December 18, 2025 Executive Order directing the Attorney General to expedite marijuana’s move from Schedule I to Schedule III has created a unique window of opportunity. With rescheduling now in motion, the political and regulatory landscape has shifted enough to make banking reform more palatable even to cautious lawmakers.

What the SAFER Banking Act Would Actually Do

At its core, the Secure and Fair Enforcement Regulation Banking Act would prohibit federal banking regulators from penalizing financial institutions that serve state-legal cannabis businesses. Because marijuana remains federally illegal, banks and credit unions currently risk enforcement action, fines, or loss of federal insurance if they open accounts, provide loans, or process payments for cannabis companies.

The result is an industry still overwhelmingly cash-based. The National Cannabis Industry Association estimates more than 70% of cannabis businesses lack access to basic banking. This forces operators to handle large amounts of cash, creating security risks, complicating tax compliance (especially under Section 280E), and blocking access to credit markets that every other legal industry takes for granted.

Key Updates in the 2026 Version

This iteration includes two important expansions:

• Ancillary business protections: Previous versions focused narrowly on “plant-touching” operators (cultivators, manufacturers, dispensaries). The 2026 bill explicitly extends safe harbor to landlords, technology vendors, accountants, security firms, and other ancillary service providers.

• Hemp operator coverage: In response to the evolving hemp landscape and the upcoming November 2026 total-THC definition change, the bill adds protections for financial institutions serving state-legal hemp businesses.

These additions broaden the coalition of supporters and address real-world pain points beyond core cannabis operators.

Political Math and Path Forward

The bipartisan cosponsor list signals growing recognition that banking reform is a public safety and compliance issue, not a direct vote on legalization. As one Republican cosponsor noted, “You can be against legalization and still believe that legal businesses should have bank accounts.”

The bill has been referred to the Senate Banking Committee. Chairman Tim Scott has indicated openness to a hearing, though his personal stance remains unclear. Previous versions passed the House multiple times but died in the Senate. Proponents hope the current rescheduling momentum and narrower focus will improve its chances.

Industry Impact If Passed

Passage would not legalize marijuana or alter its scheduling status. It would, however, open the door to:

• Basic deposit accounts and payment processing

• Business loans and lines of credit

• Tailored insurance products

• Merchant services allowing credit and debit card acceptance at dispensaries

Analysts estimate banking access alone could reduce operating costs for the average dispensary by 5-10% while dramatically lowering cash-related security incidents.

The SAFER Banking Act represents a practical, incremental step that enjoys broader support than full legalization. With Trump’s EO providing fresh momentum and a more focused bill text, 2026 may finally be the year cannabis businesses gain legitimate access to the banking system—regardless of where full federal reform ultimately lands.

The Sunshine State Is Performing

Florida’s medical marijuana market delivered its strongest monthly performance of 2026 in March, generating $176.85 million in sales according to Headset data. The robust figure pushed first-quarter sales to $484.2 million, a 7% increase from roughly $450 million in the same period of 2025.

Monthly breakdowns show January at $160.2 million, February at $147.1 million, and March reaching $176.9 million. The upward trend signals continued resilience in one of the nation’s largest and most mature medical cannabis programs.

Product mix in March reinforced traditional preferences. Flower remained the clear leader, accounting for 45% of total sales. Vape products followed at 24%, while edibles represented 14%. Concentrates and prerolls each captured 6.5%, with the balance spread across other categories. Together, vapes and edibles made up 38% of sales, indicating patients are gradually diversifying beyond smokables while flower continues to serve as the market’s foundation.

Florida’s steady growth reflects strong patient demand, a well-established dispensary network, and consistent product availability. The state’s medical-only framework has produced reliable revenue even as many other markets face pricing pressure and oversupply.

If current trends hold, Florida is on pace for another record year in 2026. The March performance—highest monthly total so far—suggests the market has momentum heading into the second quarter.

For operators and investors, the data highlights Florida’s enduring strength as a medical cannabis powerhouse. While adult-use discussions continue at the state level, the existing medical program continues to deliver robust, diversified sales across product categories.

The combination of high flower loyalty and growing acceptance of vapes and edibles points to a mature patient base that values both traditional and modern consumption methods. As Florida’s medical market matures, sustained growth in Q1 reinforces its status as one of the most stable and significant cannabis markets in the country.

🗞️ The News

📺 YouTube

Trump DOJ Shift Raises Questions on Rescheduling | TTB Presented by Flowhub

What we will cover:

✅ A major shakeup at the Department of Justice is now front and center — and it could have real implications for cannabis rescheduling.

In the latest Trade To Black podcast, presented by Flowhub, Shadd Dales and Anthony Varrell are joined by Michael Bronstein, President of the American Trade Association for Cannabis and Hemp (ATACH), to break down what Pam Bondi’s firing means for U.S. cannabis policy.

With Bondi out, Acting Attorney General Todd Blanche has stepped in. At the same time, EPA Administrator Lee Zeldin is being mentioned as the leading candidate for the permanent role.

The key question is simple — does this speed up rescheduling, or does it slow things down?

Trump’s December 18, 2025 executive order directed the DOJ to move cannabis from Schedule I to Schedule III. That would eliminate 280E, expand research, and bring more clarity to the industry. But the timeline now depends on who is leading the DOJ and how they approach the process.